Hepalys Pharma is a private, late-stage clinical biopharmaceutical company in Japan committed to the development of innovative therapeutics that address unmet needs in the management of liver disease for Japanese and Asian patients.
Hepalys serves as a catalyst to improve access to novel therapies for Asian patients with liver disease by addressing the growing issues of “drug lag” and “drug loss,” where innovative medicines accessible to patients in the US and Europe are not available in Japan and Asia. One reason for this is that an increasing number of new medicines approved in the US and Europe are developed and commercialized by emerging biopharma companies without a presence in Japan and Asia. Hepalys partners with these emerging biopharma companies to bring their innovative products to Japan and Asia, accelerating development, commercialization, and patient access.

Hepalys Pharma

Org chart

Teams

Offices